Karageorgopoulos DE, Allen J, Bhagani S. Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a “special population”? World J Hepatol 2015; 7(15): 1936-1952 [PMID: 26244068 DOI: 10.4254/wjh.v7.i15.1936]
Corresponding Author of This Article
Dr. Sanjay Bhagani, BSc, MB, ChB, FRCP, Department of Infectious Diseases/HIV Medicine, Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, United Kingdom. s.bhagani@nhs.net
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Jul 28, 2015; 7(15): 1936-1952 Published online Jul 28, 2015. doi: 10.4254/wjh.v7.i15.1936
Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a “special population”?
Drosos E Karageorgopoulos, Joanna Allen, Sanjay Bhagani
Drosos E Karageorgopoulos, Joanna Allen, Sanjay Bhagani, Department of Infectious Diseases/HIV Medicine, Royal Free London NHS Foundation Trust, London NW3 2QG, United Kingdom
Sanjay Bhagani, Research Department of Infection, UCL Medical School, Royal Free Hospital, London NW3 2QG, United Kingdom
Author contributions: Karageorgopoulos DE and Allen J equally contributed to the work; Bhagani S contributed to the work also.
Conflict-of-interest statement: Karageorgopoulos DE and Allen J: There are no conflicts of interest. Bhagani S has received honoraria/speakers fees and travel grants from Abbvie, BMS, Gilead, Janssen, MSD and ViiV.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Sanjay Bhagani, BSc, MB, ChB, FRCP, Department of Infectious Diseases/HIV Medicine, Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, United Kingdom. s.bhagani@nhs.net
Received: February 11, 2015 Peer-review started: February 12, 2015 First decision: March 20, 2015 Revised: June 24, 2015 Accepted: July 21, 2015 Article in press: July 23, 2015 Published online: July 28, 2015 Processing time: 178 Days and 11.3 Hours
Core Tip
Core tip: This manuscript focuses on hepatitis C virus/human immunodeficiency virus (HIV) co-infection, two intersecting epidemics with great global health interest. It reviews the epidemiology, pathogenesis and natural history of chronic hepatitis C in HIV infected individuals. It also reviews the impact of antiretroviral therapy on the natural history of chronic hepatitis C and the liver. Moreover, it shows that the outcomes of treatment with the newer direct acting antivirals against hepatitis C are similar in the mono-infected and co-infected patients, providing informative data extracted from relevant clinical trials. It argues that HIV infected individuals should no longer be designated as a “special population” among those with chronic hepatitis C, as this could delay their access to the new treatments.
